Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-protein 4 agent associated with cytotoxic T lymphocytes in patients with advanced solid tumors.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501089-22-00

Acronym

ITF/3756/01

Enrollment

Registered

2022-11-09

Start date

2022-11-29

Completion date

Unknown

Last updated

2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026